Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008903529> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2008903529 endingPage "1986" @default.
- W2008903529 startingPage "1986" @default.
- W2008903529 abstract "We agree with the comments of Dr. Kalogerakos [1] in his letter regarding the recent article [2] in which we describe our nodal response rates following neoadjuvant endocrine therapy and neoadjuvant chemotherapy for breast cancer. Pathologic complete response (pCR) rates following neoadjuvant systemic therapy are predictive of long-term survival benefits [3]. Our results demonstrate that pCR rates may differ between the primary breast tumor and the nodal tissue within an individual patient. Of the 19 patients who had a complete nodal pathologic response to neoadjuvant chemotherapy, only 4 (21%) also had a complete response in the breast. Conversely, there were 12 (17%) patients who had a complete pathological response in the breast following neoadjuvant chemotherapy, but had persistent disease in the nodal tissue. Future neoadjuvant trials will need to address not only the primary breast tumor response but also the nodal response in determining the pCR and its relationship to recurrence rates and overall survival. We recognize the limitations of our single-institution, retrospective study in its inability to identify the patient and tumor characteristics that may predict a pCR following neoadjuvant systemic therapy. The only factor associated with a difference in the rate of a nodal pCR was the type of neoadjuvant therapy used; all 19 patients with a nodal pCR received neoadjuvant chemotherapy and none received neoadjuvant endocrine therapy (P 0.05). The reasons for this absence of a nodal pCR following neoadjuvant endocrine therapy are unclear. Perhaps the mechanism of action for endocrine agents differs in such a way as to result in less tumoricidal activity than that of chemotherapeutic agents. To be able to predict which specific treatments will benefit which specific patients and result in the highest overall pCR rates for all neoadjuvant regimens must be the ultimate goal of future trials. This will allow physicians to personalize individual patient treatment and optimize outcomes." @default.
- W2008903529 created "2016-06-24" @default.
- W2008903529 creator A5050528770 @default.
- W2008903529 date "2010-04-09" @default.
- W2008903529 modified "2023-09-26" @default.
- W2008903529 title "The Importance of Complete Pathologic Response After Neoadjuvant Systemic Treatment in Breast Cancer Research and Practice: Reply" @default.
- W2008903529 cites W2012341628 @default.
- W2008903529 cites W2028747594 @default.
- W2008903529 cites W2096145980 @default.
- W2008903529 doi "https://doi.org/10.1007/s00268-010-0552-y" @default.
- W2008903529 hasPublicationYear "2010" @default.
- W2008903529 type Work @default.
- W2008903529 sameAs 2008903529 @default.
- W2008903529 citedByCount "0" @default.
- W2008903529 crossrefType "journal-article" @default.
- W2008903529 hasAuthorship W2008903529A5050528770 @default.
- W2008903529 hasBestOaLocation W20089035291 @default.
- W2008903529 hasConcept C121608353 @default.
- W2008903529 hasConcept C126322002 @default.
- W2008903529 hasConcept C138816342 @default.
- W2008903529 hasConcept C141071460 @default.
- W2008903529 hasConcept C142724271 @default.
- W2008903529 hasConcept C143998085 @default.
- W2008903529 hasConcept C160022790 @default.
- W2008903529 hasConcept C185926286 @default.
- W2008903529 hasConcept C2776694085 @default.
- W2008903529 hasConcept C2777010666 @default.
- W2008903529 hasConcept C2778091340 @default.
- W2008903529 hasConcept C2778292576 @default.
- W2008903529 hasConcept C2778789114 @default.
- W2008903529 hasConcept C2780120127 @default.
- W2008903529 hasConcept C3019096185 @default.
- W2008903529 hasConcept C530470458 @default.
- W2008903529 hasConcept C61434518 @default.
- W2008903529 hasConcept C71924100 @default.
- W2008903529 hasConceptScore W2008903529C121608353 @default.
- W2008903529 hasConceptScore W2008903529C126322002 @default.
- W2008903529 hasConceptScore W2008903529C138816342 @default.
- W2008903529 hasConceptScore W2008903529C141071460 @default.
- W2008903529 hasConceptScore W2008903529C142724271 @default.
- W2008903529 hasConceptScore W2008903529C143998085 @default.
- W2008903529 hasConceptScore W2008903529C160022790 @default.
- W2008903529 hasConceptScore W2008903529C185926286 @default.
- W2008903529 hasConceptScore W2008903529C2776694085 @default.
- W2008903529 hasConceptScore W2008903529C2777010666 @default.
- W2008903529 hasConceptScore W2008903529C2778091340 @default.
- W2008903529 hasConceptScore W2008903529C2778292576 @default.
- W2008903529 hasConceptScore W2008903529C2778789114 @default.
- W2008903529 hasConceptScore W2008903529C2780120127 @default.
- W2008903529 hasConceptScore W2008903529C3019096185 @default.
- W2008903529 hasConceptScore W2008903529C530470458 @default.
- W2008903529 hasConceptScore W2008903529C61434518 @default.
- W2008903529 hasConceptScore W2008903529C71924100 @default.
- W2008903529 hasIssue "8" @default.
- W2008903529 hasLocation W20089035291 @default.
- W2008903529 hasOpenAccess W2008903529 @default.
- W2008903529 hasPrimaryLocation W20089035291 @default.
- W2008903529 hasRelatedWork W188225540 @default.
- W2008903529 hasRelatedWork W1982287328 @default.
- W2008903529 hasRelatedWork W2008903529 @default.
- W2008903529 hasRelatedWork W2017717669 @default.
- W2008903529 hasRelatedWork W3189249985 @default.
- W2008903529 hasRelatedWork W4220715396 @default.
- W2008903529 hasRelatedWork W4239413849 @default.
- W2008903529 hasRelatedWork W4252179252 @default.
- W2008903529 hasRelatedWork W4292646811 @default.
- W2008903529 hasRelatedWork W4318914411 @default.
- W2008903529 hasVolume "34" @default.
- W2008903529 isParatext "false" @default.
- W2008903529 isRetracted "false" @default.
- W2008903529 magId "2008903529" @default.
- W2008903529 workType "article" @default.